Finanzas de Alzamend Neuro Inc (ALZN)ALZNAlzamend Neuro Inc

Evaluating the bottom line, Alzamend Neuro Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -163.23%, provide a clear picture of how effectively ALZN converts its operational activities into shareholder value.

In the context of the broader market, ALZN competes directly with industry leaders such as UPC and KPRX. With a market capitalization of $6.81M, it holds a significant position in the sector. When comparing efficiency, ALZN's gross margin of N/A stands against UPC's 36.99% and KPRX's N/A. Such benchmarking helps identify whether Alzamend Neuro Inc is trading at a premium or discount relative to its financial performance.

Alzamend has shown a concerning trend in net income, with losses increasing each quarter, culminating in a net income of -2,869,949 USD for Q4 2026. The company has a current ratio of 1.31, indicating it can cover its short-term liabilities but is trending down from previous quarters.